Jatiani SS, Baker SJ, Silverman LR, Reddy EP: Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes & cancer. 2010, 1 (10): 979-993. 10.1177/1947601910397187.
Article
CAS
Google Scholar
Watson CJ, Neoh K: The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol. 2008, 19 (4): 401-406. 10.1016/j.semcdb.2008.07.021.
Article
CAS
PubMed
Google Scholar
Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9 (11): 798-809. 10.1038/nrc2734.
Article
CAS
PubMed
Google Scholar
Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA: Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer. 2009, 9: 81-10.1186/1471-2407-9-81.
Article
PubMed Central
PubMed
Google Scholar
Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP: STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012, 7 (2): e30820-10.1371/journal.pone.0030820.
Article
PubMed Central
CAS
PubMed
Google Scholar
Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002, 8 (4): 945-954.
CAS
Google Scholar
Cimica V, Chen HC, Iyer JK, Reich NC: Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS One. 2011, 6 (5): e20188-10.1371/journal.pone.0020188.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mankan AK, Greten FR: Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs. 2011, 20 (9): 1263-1275. 10.1517/13543784.2011.601739.
Article
CAS
PubMed
Google Scholar
Johnston PA, Grandis JR: STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011, 11 (1): 18-26. 10.1124/mi.11.1.4.
Article
PubMed Central
CAS
PubMed
Google Scholar
Leeman RJ, Lui VW, Grandis JR: STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006, 6 (3): 231-241. 10.1517/14712598.6.3.231.
Article
CAS
PubMed
Google Scholar
Darnell JE, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994, 264 (5164): 1415-1421. 10.1126/science.8197455.
Article
CAS
PubMed
Google Scholar
Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998, 18 (5): 2545-2552.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H, Duan Z: Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2010, 28 (7): 971-978.
CAS
Google Scholar
Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P: Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clin Exp Metastasis. 2012, 29 (6): 615-624. 10.1007/s10585-012-9475-3.
Article
CAS
PubMed
Google Scholar
Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J, Fang JY: Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berl). 2012, 90 (9): 1037-1046. 10.1007/s00109-012-0869-0.
Article
CAS
Google Scholar
Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, et al: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer. 2007, 7: 111-10.1186/1471-2407-7-111.
Article
PubMed Central
PubMed
Google Scholar
Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S: Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr Blood Cancer. 2012, 58 (3): 327-333. 10.1002/pbc.23341.
Article
PubMed
Google Scholar
Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N: Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2012, 118 (18): 4597-4605. 10.1002/cncr.27414.
Article
PubMed Central
PubMed
Google Scholar
Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA: The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer. 2011, 11: 112-10.1186/1471-2407-11-112.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 2010, 12 (1): 39-50.
Article
PubMed Central
CAS
PubMed
Google Scholar
Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, et al: Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012, 30 (3): 916-926. 10.1007/s10637-011-9645-1.
Article
CAS
PubMed
Google Scholar
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3 (6): 1101-1108. 10.1038/nprot.2008.73.
Article
CAS
PubMed
Google Scholar
Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.
Article
CAS
PubMed
Google Scholar
Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat. 1979, 6 (2): 65-70.
Google Scholar
Jonckheere AR: A distribution-free k-sample test against ordered alternatives. Biometrika. 1954, 41 (1/2): 133-145. 10.2307/2333011.
Article
Google Scholar
Terpstra TJ: The asymptotic normality and consistency of Kendall’s test against trend, when ties are present in one ranking. Indigationes Mathematicase. 1952, 14: 327-333.
Article
Google Scholar
Mack GA, Wolfe DA: K-sample rank tests for umbrella alternatives. J Am Stat Assoc. 1981, 76 (373): 175-181.
Google Scholar
Juneau P: Nonparametric inference for ordered alternatives in a one-way layout using the SAS system. MWSUG Conference Procedings. 2006, SD11: 1-14.
Google Scholar
Withrow SJ, Powers BE, Straw RC, Wilkins RM: Comparative aspects of osteosarcoma Dog versus man. Clin Orthop Relat Res. 1991, 270: 159-168.
PubMed
Google Scholar
Withrow SJ, Khanna C: Bridging the gap between experimental animals and humans in osteosarcoma. Cancer Treat Res. 2009, 152: 439-446. 10.1007/978-1-4419-0284-9_24.
Article
PubMed
Google Scholar
Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C: Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: The Italian Sarcoma Group Experience (1983–2006). Cancer. 2012, 118 (20): 5050-5059. 10.1002/cncr.27493.
Article
PubMed
Google Scholar
Tu B, Du L, Fan QM, Tang Z, Tang TT: STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012, 325 (1): 80-88. 10.1016/j.canlet.2012.06.006.
Article
CAS
PubMed
Google Scholar
Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA: Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer. 2011, 11: 125-10.1186/1471-2407-11-125.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z: Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer. 2010, 10: 187-10.1186/1471-2407-10-187.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zhang X, Liu P, Zhang B, Wang A, Yang M: Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet. 2010, 197 (1): 46-53. 10.1016/j.cancergencyto.2009.10.004.
Article
CAS
PubMed
Google Scholar
Bourguignon LY, Peyrollier K, Xia W, Gilad E: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008, 283 (25): 17635-17651. 10.1074/jbc.M800109200.
Article
PubMed Central
CAS
PubMed
Google Scholar
Chen Z, Huang C, Yang YL, Ding Y, Ou-Yang HQ, Zhang YY, Xu M: Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells. Acta Pharmacol Sin. 2012, 33 (1): 101-108. 10.1038/aps.2011.164.
Article
PubMed Central
PubMed
Google Scholar
Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, et al: Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012, 83 (10): 1456-1464. 10.1016/j.bcp.2012.02.010.
Article
PubMed Central
CAS
PubMed
Google Scholar
Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ: Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One. 2012, 7 (4): e35513-10.1371/journal.pone.0035513.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, Bhasin D, Regan N, Lin L, Chan C, et al: LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer. 2009, 100 (1): 106-112. 10.1038/sj.bjc.6604793.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lin L, Benson DM, DeAngelis S, Bakan CE, Li PK, Li C, Lin J: A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer. 2012, 130 (6): 1459-1469. 10.1002/ijc.26152.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gustafson DL, Rastatter JC, Colombo T, Long ME: Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci. 2002, 91 (6): 1488-1501. 10.1002/jps.10161.
Article
CAS
PubMed
Google Scholar